3 New Strong Buy Ratings from Top-Rated Analysts: 11/04/2025
Are you ready for this jelly? Here’s the latest from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Gilead Sciences (GILD) turns scientific wins into serious investor momentum
- Cardinal Health (CAH) enjoys strong sentiment in a trending sector
- Emcor Group (EME) has gained over 90% since we first alerted. Are you watching?
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
How to Become Your Own Bank (And Earn 30-400% Annually) A former Wall Street insider with a CFA Charter is showing crypto investors how to "become their own bank". This select group is using the same liquidity strategy BlackRock uses to dominate traditional markets... except in crypto where returns are exponentially higher. This allows them to generate income regardless of market direction. Regular investors are already earning up to triple-digit annual returns. Click here for the free training to learn how you can earn an extra 30-400% on your digital assets.1. Gilead Sciences (NASDAQ: GILD)
Gilead Sciences isn’t resting on its laurels. With powerhouse HIV treatments fueling growth, new cancer drugs earning headlines, and a robust R&D engine firing on all cylinders, this biotech leader is turning scientific wins into serious investor momentum.
Zen Rating: B (Buy) — see full analysis
Recent Price: $119.79 — get current quote
Max 1-year forecast: $150.00
Why we're watching:
- Strong analyst support: Among the top-rated analysts we track, GILD enjoys 18 Strong Buy, 9 Buy, and 6 Hold ratings. See the ratings
- Wells Fargo researcher John Smith recently raised the price target after Gilead's HIV franchise outperformed in Q3 and the company won the 2025 Prix Galien award for Yeztugo® (Lenacapavir), citing "Transformation in blood cancer care and consistent pipeline execution should support further upside."
- Strong price action: Gilead has enjoyed a 7% surge in the past month and 30%+ annual gains
- Industry ranking context: GILD is currently the 7th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A. (See more winners in the industry here)
- With a Zen Rating of B (Buy), GILD is in good company — B-rated stocks have historically delivered +19.88%/yr.
- The Component Grades shaping that overall rating show specific areas of strength: GILD has above-average rankings for Financials, Safety, and Value. (See all 7 Zen Component Grades here)
2. Cardinal Health (NYSE: CAH)
Cardinal Health is one of the largest distributors of pharmaceuticals and medical products in the U.S., serving 75% of American hospitals. The company is benefiting from resilient healthcare spending, strategic acquisitions, and strong sentiment in the defensive medical distribution sector.
Zen Rating: B (Buy) — see full analysis
Recent Price: $190.77 — get current quote
Max 1-year forecast: $220.00
Why we're watching:
- Analyst support: CAH currently has 14 Strong Buy, 7 Buy, and 4 Hold ratings among the analysts we track. See the ratings
- A flurry of said ratings are brand-new, following the company’s recent earnings report; for example, Kevin Caliendo of UBS (a top 20% analyst) just maintained their street-high $220 price target.
- In addition to having an above-average Zen Rating of B, it’s in a top-rated industry: The Medical Distribution Industry currently earns an A, and CAH is the top pick within it — ranked #1 of 7 stocks. (See the rest of the list here)
- CAH earns strong Component Grades — an A for both Safety and Sentiment, where it ranks in the top 10% of stocks, and an above-average B for Growth — a solid mix for investors looking for security without price action stalling out. (See all 7 Zen Component Grades here)
3. Emcor Group (NYSE: EME)
Emcor is a leading specialty construction firm with expertise in power transmission, voice & data communications, and fiber optics. It also just so happens to be part of our market-beating Zen Investor portfolio — a pick that has gained 92% since we first alerted. The company is riding some serious growth trends — and the stock’s already impressive rally isn’t showing any signs of stopping.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $675.78 — get current quote
Max 1-year forecast: $800.00
Why we're watching:
- Smart money is digging EME, as evidenced by 10 Strong Buy, 5 Buy ratings among the analysts we track. See the ratings
- Analyst commentary emphasizes EMCOR’s 51.5% annual return, robust momentum, and leadership in complex infrastructure.
- A-Rated Industry: The Engineering & Construction Industry is among the top-rated market niches we track; EME is the 8th highest-rated stock out of 45.
- An excellent Zen Rating: With its Strong Buy (A) rating, EME is in a class of stocks that have enjoyed +32.52% returns per year.
- Key areas of strength as revealed by the Component Grades include Growth and Momentum, where EME earns above-average Bs, ranking in the top 25% of stocks, indicating there’s more gas in the tank for this high-potential ticker. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.